Title of article
Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature
Author/Authors
Jack F. Jacoub، نويسنده , , Uma Suryadevara، نويسنده , , Vivian Pereyra، نويسنده , , Donna Col?n، نويسنده , , Antonio Fontelonga، نويسنده , , F. Roy MacKintosh، نويسنده , , Stephen W. Hall، نويسنده , , Jo?o L. Ascens?o، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2006
Pages
8
From page
1443
To page
1450
Abstract
Objective
Given the potential to limit cost, we conducted a pilot study evaluating delayed, low-dose granulocyte colony-stimulating factor (G-CSF) following chemotherapy for the procurement of peripheral blood progenitor cells (PBPCs) for autologous transplantation and reviewed the relevant literature.
Patients and methods
Twenty-eight patients with various malignancies received cyclophosphamide 4 gm/m2 and paclitaxel 170 mg/m2 followed by G-CSF 300 μg/d or 480 μg/d starting day +5 until two to four daily large volume leukapheresis yielded ≥5.0 × 106 CD34+ cells. We searched MEDLINE, Pubmed, and EMBASE databases from 1990 to the present to identify papers on PBPC procurement using delayed G-CSF (starting day +4 or later) following chemotherapy.
Results
G-CSF was administered for a median of 9 days at an average cost of $1260 USD per 70-kg patient. Collection was initiated at a median of 12 days after chemotherapy. A median 2.5 (range 2–4) apheresis were performed yielding an average daily CD34+ collection of 6.9 × 106 /kg (range 0.35–56.7). After one apheresis, 82% and 57% of patients collected ≥2.5 × 106/kg and ≥5.0 × 106/kg, respectively. Ultimately, 89% collected ≥5.0 × 106/kg. Febrile neutropenia and catheter-related infection developed in five and two patients, respectively. All patients proceeded to transplantation and engrafted successfully with a median of 14.9 × 106/kg (range 1.05–113) cells infused. Eleven published reports were identified involving 590 patients of whom 498 received G-CSF at a dose range of 250 μg/d to 10 μg/kg/d starting day +4 to 15 for a period of 4 to 9 days for PBPC procurement. Among these reports, 62 to 100% and 33 to 96% of patients collected ≥2 to 2.5 × 106 and ≥5.0 × 106 CD34+ cells, respectively.
Conclusion
The use of delayed, low-dose G-CSF plus chemotherapy for stem cell mobilization was feasible and provides further evidence supporting this potentially cost-effective strategy. A review of the literature supports our findings and emphasizes the need for larger studies to address this issue.
Journal title
Experimental Hematology
Serial Year
2006
Journal title
Experimental Hematology
Record number
514451
Link To Document